Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

Sponsor
Tongji Hospital
Study ID
NCT06152822
Phase
PHASE2
Status
Unknown

Conditions

  • Breast Cancer With Brain Metastases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study intends to conduct a small, prospective, single-center clinical study to explore and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab in HER2-positive advanced breast cancer with brain metastases.The overall objective is to provide a new drug regimen for HER2 positive breast cancer patients with brain metastases by balancing survival benefits and patient quality of life.

Key Dates

First listed
Dec 1, 2023
Start date
Nov 30, 2023
Status verified
Nov 2023
Primary completion
Nov 30, 2024
Completion
Nov 30, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    pyrotinib+capecitabine+bevacizumab

Primary Outcome Measure

Objective response rate in the CNS [ Time Frame: Up to 2 years ]

Central Contacts